Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H26ClN3OS |
Molecular Weight | 403.969 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCN1CCN(CCCN2C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1
InChI
InChIKey=RGCVKNLCSQQDEP-UHFFFAOYSA-N
InChI=1S/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2
Molecular Formula | C21H26ClN3OS |
Molecular Weight | 403.969 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Perphenazine is a relatively high potency phenothiazine that blocks dopamine 2 receptors predominantly, but also may possess antagonist actions at histamine 1 and cholinergic M1 and alpha 1 adrenergic receptors in the vomiting center leading to reduced nausea and vomiting. The drug was approved by FDA for the treatment of schizophrenia and control of severe nausea and vomiting (either alone or in combination with amitriptyline hydrochloride). Perphenazine is extensively hepatic to metabolites via sulfoxidation, hydroxylation, dealkylation, and glucuronidation; primarily metabolized by CYP2D6 to N-dealkylated perphenazine, perphenazine sulfoxide, and 7-hydroxyperphenazine (active metabolite with 70% of the activity of perphenazine) and excreted in the urine and feces.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P14416 Gene ID: 1813.0 Gene Symbol: DRD2 Target Organism: Homo sapiens (Human) Sources: http://apm.amegroups.com/article/view/1039/1266 |
0.16 nM [Ki] | ||
Target ID: P35367 Gene ID: 3269.0 Gene Symbol: HRH1 Target Organism: Homo sapiens (Human) Sources: http://apm.amegroups.com/article/view/1039/1266 |
8.0 nM [Kd] | ||
Target ID: P11229 Gene ID: 1128.0 Gene Symbol: CHRM1 Target Organism: Homo sapiens (Human) Sources: http://apm.amegroups.com/article/view/1039/1266 |
1.5 µM [Kd] | ||
Target ID: CHEMBL2094251 Sources: http://apm.amegroups.com/article/view/1039/1266 |
10.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | PERPHENAZINE Approved UsePerphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. Launch Date1988 |
|||
Preventing | PERPHENAZINE Approved UsePerphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. Launch Date1988 |
|||
Primary | PERPHENAZINE Approved UsePerphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. Launch Date1988 |
|||
Primary | PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE Approved UsePerphenazine and amitriptyline hydrochloride tablets are recommended for treatment of (1) patients with moderate to severe anxiety and/or agitation and depressed mood, (2) patients with depression in whom anxiety and/or agitation are severe, and (3) patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate. Launch Date1988 |
|||
Primary | PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE Approved UsePerphenazine and amitriptyline hydrochloride tablets are recommended for treatment of (1) patients with moderate to severe anxiety and/or agitation and depressed mood, (2) patients with depression in whom anxiety and/or agitation are severe, and (3) patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate. Launch Date1988 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
509 pg/mL |
4 mg 3 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
7-HYDROXYPERPHENAZINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
0.546 ng/mL |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
PERPHENAZINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
984 pg/mL |
4 mg 3 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
PERPHENAZINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.673 ng × h/mL |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
PERPHENAZINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.8 h |
4 mg 3 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
7-HYDROXYPERPHENAZINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
9.12 h |
16 mg single, oral dose: 16 mg route of administration: Oral experiment type: SINGLE co-administered: |
PERPHENAZINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
12 h |
4 mg 3 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
PERPHENAZINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9% |
unknown, unknown |
PERPHENAZINE unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.93 g single, oral Overdose Dose: 0.93 g Route: oral Route: single Dose: 0.93 g Co-administed with:: maprotiline, p.o(5.6 g; single) Sources: Page: p.2627, 2631triazolam, p.o(14 mg; single) salicylate |
unhealthy, 42 n = 1 Health Status: unhealthy Condition: Depression Age Group: 42 Sex: M Population Size: 1 Sources: Page: p.2627, 2631 |
Disc. AE: QT interval prolonged, Hypothermia... AEs leading to discontinuation/dose reduction: QT interval prolonged Sources: Page: p.2627, 2631Hypothermia Loss of consciousness PR interval prolonged QRS prolonged |
200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: Page: p.104 |
unhealthy, 48 n = 1 Health Status: unhealthy Condition: Schizophrenia Age Group: 48 Sex: F Population Size: 1 Sources: Page: p.104 |
Disc. AE: Coma, Hypothermia... AEs leading to discontinuation/dose reduction: Coma Sources: Page: p.104Hypothermia Tachycardia Miosis |
30 mg 1 times / day multiple, intramuscular (total daily dose) Recommended Dose: 30 mg, 1 times / day Route: intramuscular Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: Page: p.3 |
Disc. AE: Tardive dyskinesia... AEs leading to discontinuation/dose reduction: Tardive dyskinesia Sources: Page: p.3 |
30 mg 1 times / day multiple, intramuscular (total daily dose) Recommended Dose: 30 mg, 1 times / day Route: intramuscular Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p.4 |
unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: Page: p.4 |
Disc. AE: Neuroleptic malignant syndrome... AEs leading to discontinuation/dose reduction: Neuroleptic malignant syndrome Sources: Page: p.4 |
64 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 64 mg, 1 times / day Route: oral Route: multiple Dose: 64 mg, 1 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: Page: p.3 |
Disc. AE: Tardive dyskinesia... AEs leading to discontinuation/dose reduction: Tardive dyskinesia Sources: Page: p.3 |
64 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 64 mg, 1 times / day Route: oral Route: multiple Dose: 64 mg, 1 times / day Sources: Page: p.4 |
unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: Page: p.4 |
Disc. AE: Neuroleptic malignant syndrome... AEs leading to discontinuation/dose reduction: Neuroleptic malignant syndrome Sources: Page: p.4 |
20 mg single, intramuscular Studied dose Dose: 20 mg Route: intramuscular Route: single Dose: 20 mg Sources: |
unhealthy n = 1 Health Status: unhealthy Condition: Schizophrenia Population Size: 1 Sources: |
Disc. AE: Neuroleptic malignant syndrome... AEs leading to discontinuation/dose reduction: Neuroleptic malignant syndrome Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypothermia | Disc. AE | 0.93 g single, oral Overdose Dose: 0.93 g Route: oral Route: single Dose: 0.93 g Co-administed with:: maprotiline, p.o(5.6 g; single) Sources: Page: p.2627, 2631triazolam, p.o(14 mg; single) salicylate |
unhealthy, 42 n = 1 Health Status: unhealthy Condition: Depression Age Group: 42 Sex: M Population Size: 1 Sources: Page: p.2627, 2631 |
Loss of consciousness | Disc. AE | 0.93 g single, oral Overdose Dose: 0.93 g Route: oral Route: single Dose: 0.93 g Co-administed with:: maprotiline, p.o(5.6 g; single) Sources: Page: p.2627, 2631triazolam, p.o(14 mg; single) salicylate |
unhealthy, 42 n = 1 Health Status: unhealthy Condition: Depression Age Group: 42 Sex: M Population Size: 1 Sources: Page: p.2627, 2631 |
PR interval prolonged | Disc. AE | 0.93 g single, oral Overdose Dose: 0.93 g Route: oral Route: single Dose: 0.93 g Co-administed with:: maprotiline, p.o(5.6 g; single) Sources: Page: p.2627, 2631triazolam, p.o(14 mg; single) salicylate |
unhealthy, 42 n = 1 Health Status: unhealthy Condition: Depression Age Group: 42 Sex: M Population Size: 1 Sources: Page: p.2627, 2631 |
QRS prolonged | Disc. AE | 0.93 g single, oral Overdose Dose: 0.93 g Route: oral Route: single Dose: 0.93 g Co-administed with:: maprotiline, p.o(5.6 g; single) Sources: Page: p.2627, 2631triazolam, p.o(14 mg; single) salicylate |
unhealthy, 42 n = 1 Health Status: unhealthy Condition: Depression Age Group: 42 Sex: M Population Size: 1 Sources: Page: p.2627, 2631 |
QT interval prolonged | Disc. AE | 0.93 g single, oral Overdose Dose: 0.93 g Route: oral Route: single Dose: 0.93 g Co-administed with:: maprotiline, p.o(5.6 g; single) Sources: Page: p.2627, 2631triazolam, p.o(14 mg; single) salicylate |
unhealthy, 42 n = 1 Health Status: unhealthy Condition: Depression Age Group: 42 Sex: M Population Size: 1 Sources: Page: p.2627, 2631 |
Coma | Disc. AE | 200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: Page: p.104 |
unhealthy, 48 n = 1 Health Status: unhealthy Condition: Schizophrenia Age Group: 48 Sex: F Population Size: 1 Sources: Page: p.104 |
Hypothermia | Disc. AE | 200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: Page: p.104 |
unhealthy, 48 n = 1 Health Status: unhealthy Condition: Schizophrenia Age Group: 48 Sex: F Population Size: 1 Sources: Page: p.104 |
Miosis | Disc. AE | 200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: Page: p.104 |
unhealthy, 48 n = 1 Health Status: unhealthy Condition: Schizophrenia Age Group: 48 Sex: F Population Size: 1 Sources: Page: p.104 |
Tachycardia | Disc. AE | 200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: Page: p.104 |
unhealthy, 48 n = 1 Health Status: unhealthy Condition: Schizophrenia Age Group: 48 Sex: F Population Size: 1 Sources: Page: p.104 |
Tardive dyskinesia | Disc. AE | 30 mg 1 times / day multiple, intramuscular (total daily dose) Recommended Dose: 30 mg, 1 times / day Route: intramuscular Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: Page: p.3 |
Neuroleptic malignant syndrome | Disc. AE | 30 mg 1 times / day multiple, intramuscular (total daily dose) Recommended Dose: 30 mg, 1 times / day Route: intramuscular Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p.4 |
unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: Page: p.4 |
Tardive dyskinesia | Disc. AE | 64 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 64 mg, 1 times / day Route: oral Route: multiple Dose: 64 mg, 1 times / day Sources: Page: p.3 |
unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: Page: p.3 |
Neuroleptic malignant syndrome | Disc. AE | 64 mg 1 times / day multiple, oral (total daily dose) Recommended Dose: 64 mg, 1 times / day Route: oral Route: multiple Dose: 64 mg, 1 times / day Sources: Page: p.4 |
unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: Page: p.4 |
Neuroleptic malignant syndrome | Disc. AE | 20 mg single, intramuscular Studied dose Dose: 20 mg Route: intramuscular Route: single Dose: 20 mg Sources: |
unhealthy n = 1 Health Status: unhealthy Condition: Schizophrenia Population Size: 1 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/10460810/ Page: abstract |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/10460810/ Page: abstract |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/10460810/ Page: abstract |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/10460810/ Page: abstract |
yes [IC50 1.5 uM] | |||
Page: abstract |
yes [IC50 38.2 uM] | |||
Sources: https://dmd.aspetjournals.org/content/44/3/378.short Page: 42.0 |
yes [IC50 66.2 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/10460810/ Page: abstract |
yes [Ki 65.1 uM] | |||
Sources: https://iv.iiarjournals.org/content/23/6/943.short Page: 945.0 |
yes | |||
Page: 962.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 961.0 |
yes | |||
Page: 510.0 |
yes | |||
Page: 961.0 |
yes | |||
Page: 961.0 |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 1033.0 |
||||
Page: abstract |
PubMed
Title | Date | PubMed |
---|---|---|
The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy. | 1967 |
|
Side-effects of phenothiazines. | 1967 Apr 1 |
|
Phenothiazines in early labour. | 1967 Feb 11 |
|
Drug-induced extrapyramidal symptoms: their incidence and treatment. | 1967 Jan |
|
Specific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients. | 1967 Mar-Apr |
|
Phenothiazines and diabetes in hospitalized women. | 1968 Jan |
|
Dystonic reaction to perphenazine. | 1969 Aug 9 |
|
Perphenazine dystonia presenting as recurrent dislocation of the jaw. | 1969 Jan |
|
Increased sensitivity to neuroleptics in rats with lesions of the central nervous system. | 1972 |
|
Idiosyncratic responses to phenothiazines. | 1972 Jan 22 |
|
The mechanism of the potentiating effect of antidepressant drugs on the protective influenc oe of diphenhydramine in experimental catatonia. The role of histamine. | 1974 |
|
Letter: Side-effects of perphenazine. | 1975 Jun 21 |
|
Asymptomatic idiopathic syndrome of prolonged Q-T interval in a 45-year-old woman. Ventricular tachyarrhythmias precipitated by hypokalemia and therapy with amitriptyline and prephenazine. | 1977 Feb |
|
Drug-induced anaphylaxis, convulsions, deafness, and extrapyramidal symptoms. | 1977 Mar 12 |
|
[Acute dystonia in children. 2 cases caused by perphenazine (Trilafon)]. | 1978 Mar 10 |
|
Death attributed to ventricular arrhythmia induced by thioridazine in combination with a single Contac C capsule. | 1978 Oct 7 |
|
Electrophysiologic studies of perphenazine and protriptyline in a patient with psychotropic drug-induced ventricular fibrillation. | 1979 Aug |
|
Seven cases of somnambulism induced by drugs. | 1979 Jul |
|
Metoclopramide and dystonic reactions in Sardinians. | 1979 Jun 23 |
|
Toxic psychosis with cimetidine. | 1979 May |
|
Pituitary sensitivity to LHRH in hyperprolactinemia induced by perphenazine and renal pituitary transplants in female rats. | 1980 Apr |
|
Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. | 1981 |
|
Actions of clonidine on convulsions and behaviour. | 1981 Jul |
|
Prolactin and the small intestine. Effect of hyperprolactinaemia on mucosal structure in the rat. | 1981 Jul |
|
Tricyclic antidepressants and alcoholic blackouts. | 1981 Jun |
|
Dose-response relationships of perphenazine in the treatment of acute psychoses. | 1982 |
|
Cerebellar syndrome following neuroleptic induced heat stroke. | 1983 Feb |
|
Unique sensitivity of Hb Zürich to oxidative injury by phenazopyridine: reversal of the effects by elevating carboxyhemoglobin levels in vivo and in vitro. | 1983 Jun |
|
Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes. | 1984 Sep |
|
Pharmacology in vivo of the phenylindan derivative, Lu 19-005, a new potent inhibitor of dopamine, noradrenaline and 5-hydroxytryptamine uptake in rat brain. | 1985 Apr |
|
GABAergic, dopaminergic and cholinergic interactions in perphenazine-induced catatonia in rats. | 1985 Dec |
|
Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group. | 1986 |
|
A case of progressive hemichorea responsive to high-dose reserpine. | 1986 Mar |
|
Tourette-like syndrome following low dose short-term neuroleptic treatment. | 1986 May |
|
Neurologic approach to drug-induced movement disorders: a study of 125 patients. | 1990 May |
|
Extrapyramidal symptoms and their relationship to clinical efficacy under perphenazine treatment. A controlled prospective handwriting-test study in 22 acutely ill schizophrenic patients. | 1991 Jul |
|
Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. | 1993 Dec |
|
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. | 1994 Mar |
|
The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery. | 1995 Jul |
|
BMY-14802 reversed the sigma receptor agonist-induced neck dystonia in rats. | 1996 |
|
Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report. | 1997 Dec 1 |
|
Induction of mania by risperidone resistant to mood stabilizers. | 1997 Feb |
|
Olanzapine use in women with antipsychotic-induced hyperprolactinemia. | 1998 Oct |
|
Permanent lithium-induced cerebellar toxicity: three cases and review of literature. | 2007 Mar 15 |
|
Protective effect of cyclooxygenase (COX)-inhibitors against drug-induced catatonia and MPTP-induced striatal lesions in rats. | 2009 Dec |
|
Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions. | 2010 Apr 11 |
|
Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting. | 2010 Dec |
|
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. | 2010 Feb 23 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
|
Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine. | 2014 Jun |
Patents
Sample Use Guides
Moderately disturbed nonhospitalized patients with schizophrenia: 4 to 8 mg t.i.d. initially; reduce as soon as possible to minimum effective dosage. Hospitalized patients with schizophrenia: 8 to 16 mg b.i.d. to q.i.d.; avoid dosages in excess of 64 mg daily. Severe nausea and vomiting in adults: 8 to 16 mg daily in divided doses; 24 mg occasionally may be necessary; early dosage reduction is desirable.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12043843
Perphenazine (10-100 microM) was administered, either alone or combined with dopamine, to primary mouse neuronal or intact brain culture and to a human neuroblastoma (NB) cell line (SK-N-SH). Cell viability (measured by neutral red and alamar blue), DNA fragmentation (flow cytometry-NB) were determined. Neuroblastoma: perphenazine decreased viability by 87%.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:27:42 GMT 2023
by
admin
on
Fri Dec 15 16:27:42 GMT 2023
|
Record UNII |
FTA7XXY4EZ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175746
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
||
|
WHO-VATC |
QN05AB03
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
||
|
LIVERTOX |
NBK548366
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
||
|
NCI_THESAURUS |
C29710
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
||
|
NDF-RT |
N0000007544
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
||
|
NDF-RT |
N0000007544
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
||
|
NDF-RT |
N0000007544
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
||
|
WHO-ATC |
N05AB03
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
8076
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | RxNorm | ||
|
637
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
SUB09736MIG
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
CHEMBL567
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
DTXSID1023441
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
DB00850
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
FTA7XXY4EZ
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
D010546
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
FTA7XXY4EZ
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
PERPHENAZINE
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
C29355
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
8028
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
2113
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
150866
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
1511000
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
4748
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
100000092394
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
58-39-9
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
200-381-5
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
m8567
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | Merck Index | ||
|
3379
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
Perphenazine
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY | |||
|
209
Created by
admin on Fri Dec 15 16:27:42 GMT 2023 , Edited by admin on Fri Dec 15 16:27:42 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MINOR
PLASMA
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
MINOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
UNSPECIFIED
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||